Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
May 29, 2020 08:01 ET
|
Iovance Biotherapeutics, Inc.
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up 36.4% Overall Response Rate (ORR) Maintained SAN CARLOS, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Iovance...
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
May 28, 2020 21:30 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer...
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
May 27, 2020 16:20 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer...
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
May 27, 2020 16:01 ET
|
Iovance Biotherapeutics, Inc.
Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up Cohort 2 Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up and...
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma
May 13, 2020 17:01 ET
|
Iovance Biotherapeutics, Inc.
Median Duration of Response Not Reached at 17.0 Months of Median Study Follow Up in C-144-01 Study Oral Presentation to Include Additional Cohort 2 Data from C-144-01 Clinical Study at ASCO 2020...
Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
May 05, 2020 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies...
Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific Program
April 29, 2020 12:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020
April 27, 2020 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
April 13, 2020 17:14 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics to Present at Upcoming Conferences
March 02, 2020 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...